NHS Oxford OXCAIR and DeepLook Medical release clinical study results

New Oxford Study Finds DeepLook Medical’s FDA-Cleared Imaging Technology Improves Confidence in Cancer Detection Without Increasing False Alarms.

Clinical study demonstrates improved confidence in breast cancer detection, with virtually unchanged false-positive rates and minimal impact on radiologist workflow.

The study, titled Evaluating the Impact of the DL Precise Image Enhancement Tool on Mammographic Reading in the One Stop Breast Clinic, evaluated how the technology affected cancer detection, false-positive findings, biopsy recommendations, and interpretation time.

Key findings included:

● Reader diagnostic confidence improved: In dense and mixed-density breasts, 35% of cancers originally scored “intermediate” (M3) by the unaided reader were reclassified as “suspicious” (M4+) with DL Precise.  This represents a 5.2% increase in sensitivity.

● Preserved specificity: Specificity remained essentially unchanged, from 77.7% to 77.2%, indicating no meaningful increase in false-positive findings.

● Reading time: DL Precise added a median of minimal 13 seconds per diagnostic case.

● Greater consistency among radiologists: The spread between the highest and lowest reader-level sensitivities narrowed by 4.8 percentage points, consistent with readers converging on more

standardized assessments. See study here